Literature DB >> 8961136

Controlled delivery of antigens and adjuvants in vaccine development.

Z Zhao1, K W Leong.   

Abstract

Advances in the understanding of the pathogenesis of infectious diseases and cancer immunology have inspired many new approaches to vaccine development. Many subunit antigens and peptides that are effective for vaccination have been discovered. These subunit antigens in tum stimulate synthesis of effective adjuvants to enhance their immunogenicity. Controlled-release technology offers the potential of further improving the efficacy of conventional vaccine formulations by optimizing the temporal and spatial presentation of the-antigens and adjuvants to the immune system. The combination of sustained release and depot effect may also reduce the amount of antigens or adjuvants needed and eliminate the booster shots that are necessary for the success of many vaccinations. This review examines the contribution controlled release technology can make in various areas of vaccination, with an emphasis on tumor vaccines.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8961136     DOI: 10.1021/js9602812

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  12 in total

Review 1.  New vaccine development.

Authors:  Gregory A Poland; Dennis Murray; Ruben Bonilla-Guerrero
Journal:  BMJ       Date:  2002-06-01

Review 2.  Multifunctional dendritic cell-targeting polymeric microparticles: engineering new vaccines for type 1 diabetes.

Authors:  Benjamin G Keselowsky; Chang Qing Xia; Michael Clare-Salzler
Journal:  Hum Vaccin       Date:  2011-01-01

3.  Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?

Authors:  Pawel Kalinski; Howard Edington; Herbert J Zeh; Hideho Okada; Lisa H Butterfield; John M Kirkwood; David L Bartlett
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

4.  Extended delivery of vaccines to the skin improves immune responses.

Authors:  Jessica C Joyce; Hila E Sella; Heather Jost; Matthew J Mistilis; E Stein Esser; Pallab Pradhan; Randall Toy; Marcus L Collins; Paul A Rota; Krishnendu Roy; Ioanna Skountzou; Richard W Compans; M Steven Oberste; William C Weldon; James J Norman; Mark R Prausnitz
Journal:  J Control Release       Date:  2019-05-06       Impact factor: 9.776

5.  Evolving importance of biologics and novel delivery systems in the face of microbial resistance.

Authors:  Terry L Bowersock
Journal:  AAPS PharmSci       Date:  2002

Review 6.  Innovative strategies for co-delivering antigens and CpG oligonucleotides.

Authors:  Yogita Krishnamachari; Aliasger K Salem
Journal:  Adv Drug Deliv Rev       Date:  2009-01-19       Impact factor: 15.470

7.  Chitosan solution enhances the immunoadjuvant properties of GM-CSF.

Authors:  David A Zaharoff; Connie J Rogers; Kenneth W Hance; Jeffrey Schlom; John W Greiner
Journal:  Vaccine       Date:  2007-11-05       Impact factor: 3.641

Review 8.  Current advances in research and clinical applications of PLGA-based nanotechnology.

Authors:  Jian-Ming Lü; Xinwen Wang; Christian Marin-Muller; Hao Wang; Peter H Lin; Qizhi Yao; Changyi Chen
Journal:  Expert Rev Mol Diagn       Date:  2009-05       Impact factor: 5.225

Review 9.  Current status of autologous breast tumor cell-based vaccines.

Authors:  Samantha L Kurtz; Sruthi Ravindranathan; David A Zaharoff
Journal:  Expert Rev Vaccines       Date:  2014-10-13       Impact factor: 5.217

Review 10.  Biodegradable polymeric microsphere-based vaccines and their applications in infectious diseases.

Authors:  Chi-Ying Lin; Shih-Jie Lin; Yi-Chen Yang; Der-Yuan Wang; Hwei-Fang Cheng; Ming-Kung Yeh
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.